Univariable Analysis of OS and LFS
| . | No. . | Kaplan- Meier 36-Month OS % (SE %) . | P Value . | Kaplan- Meier 36-Month LFS % (SE %) . | P Value . |
|---|---|---|---|---|---|
| Matched | 855-150 | 48.7 (5.6) | .380 | 44.8 (5.6) | .654 |
| Mismatched | 52 | 41.7 (6.9) | 39.9 (6.8) | ||
| HLA-C | |||||
| Matched | 44 | 48.6 (8.1) | .700 | 45.0 (7.8) | .858 |
| Mismatched | 385-150 | 44.6 (8.1) | 43.2 (8.1) | ||
| Not tested | 55 | 45.5 (6.7) | 41.8 (6.7) | ||
| No methotrexate | 945-150 | 47.3 (5.3) | .652 | 43.7 (5.3) | .933 |
| Methotrexate | 43 | 43.4 (7.7) | 41.3 (7.6) | ||
| Matched | |||||
| No methotrexate | 795-150 | 47.2 (5.8) | .438 | 43.0 (5.8) | .346 |
| Methotrexate | 6 | 66.7 (19.3) | 66.7 (19.3) | ||
| Mismatched | |||||
| No methotrexate | 15 | 46.7 (12.9) | .712 | 46.7 (12.9) | .699 |
| Methotrexate | 37 | 39.4 (8.2) | 37.1 (8.0) | ||
| Disease status | |||||
| CR1 | 24 | 40.4 (10.2) | .622 | 41.3 (10.1) | .596 |
| CR2 | 885-150 | 49.4 (5.5) | 45.5 (5.5) | ||
| CR3/CR4/relapse | 25 | 39.6 (9.9) | 36.0 (9.6) | ||
| CMV status | |||||
| Neg/neg | 76 | 46.3 (5.8) | .968 | 43.9 (5.8) | .935 |
| Any other | 615-150 | 44.7 (6.7) | 41.3 (6.6) | ||
| Donor gender | |||||
| Male | 715-150 | 41.5 (6.1) | .171 | 38.4 (6.0) | .137 |
| Female | 65 | 51.4 (6.3) | 48.4 (6.3) | ||
| HLA methodology | |||||
| Pre-SSP | 40 | 47.5 (7.9) | .776 | 47.5 (7.9) | .655 |
| SSP | 975-150 | 45.3 (5.2) | 40.7 (5.2) | ||
| Patient age | |||||
| <8 yr | 62 | 39.9 (6.3) | .231 | 40.1 (6.3) | .469 |
| >8 yr | 755-150 | 51.1 (6.0) | 45.3 (6.0) | ||
| TNC | |||||
| <Median | 695-150 | 46.3 (6.2) | .885 | 43.2 (6.1) | .994 |
| >Median | 68 | 45.4 (6.2) | 42.6 (6.2) |
| . | No. . | Kaplan- Meier 36-Month OS % (SE %) . | P Value . | Kaplan- Meier 36-Month LFS % (SE %) . | P Value . |
|---|---|---|---|---|---|
| Matched | 855-150 | 48.7 (5.6) | .380 | 44.8 (5.6) | .654 |
| Mismatched | 52 | 41.7 (6.9) | 39.9 (6.8) | ||
| HLA-C | |||||
| Matched | 44 | 48.6 (8.1) | .700 | 45.0 (7.8) | .858 |
| Mismatched | 385-150 | 44.6 (8.1) | 43.2 (8.1) | ||
| Not tested | 55 | 45.5 (6.7) | 41.8 (6.7) | ||
| No methotrexate | 945-150 | 47.3 (5.3) | .652 | 43.7 (5.3) | .933 |
| Methotrexate | 43 | 43.4 (7.7) | 41.3 (7.6) | ||
| Matched | |||||
| No methotrexate | 795-150 | 47.2 (5.8) | .438 | 43.0 (5.8) | .346 |
| Methotrexate | 6 | 66.7 (19.3) | 66.7 (19.3) | ||
| Mismatched | |||||
| No methotrexate | 15 | 46.7 (12.9) | .712 | 46.7 (12.9) | .699 |
| Methotrexate | 37 | 39.4 (8.2) | 37.1 (8.0) | ||
| Disease status | |||||
| CR1 | 24 | 40.4 (10.2) | .622 | 41.3 (10.1) | .596 |
| CR2 | 885-150 | 49.4 (5.5) | 45.5 (5.5) | ||
| CR3/CR4/relapse | 25 | 39.6 (9.9) | 36.0 (9.6) | ||
| CMV status | |||||
| Neg/neg | 76 | 46.3 (5.8) | .968 | 43.9 (5.8) | .935 |
| Any other | 615-150 | 44.7 (6.7) | 41.3 (6.6) | ||
| Donor gender | |||||
| Male | 715-150 | 41.5 (6.1) | .171 | 38.4 (6.0) | .137 |
| Female | 65 | 51.4 (6.3) | 48.4 (6.3) | ||
| HLA methodology | |||||
| Pre-SSP | 40 | 47.5 (7.9) | .776 | 47.5 (7.9) | .655 |
| SSP | 975-150 | 45.3 (5.2) | 40.7 (5.2) | ||
| Patient age | |||||
| <8 yr | 62 | 39.9 (6.3) | .231 | 40.1 (6.3) | .469 |
| >8 yr | 755-150 | 51.1 (6.0) | 45.3 (6.0) | ||
| TNC | |||||
| <Median | 695-150 | 46.3 (6.2) | .885 | 43.2 (6.1) | .994 |
| >Median | 68 | 45.4 (6.2) | 42.6 (6.2) |
1 patient excluded for LFS, relapse date uncertain.